Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-24 of 24 for your search:
Cancer Type/Condition:
Non-Hodgkin lymphoma, child
Stage/Subtype:
stage IV childhood anaplastic large cell lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
2.
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-110
, SUN08-01, NCT00704054
3.
Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 25
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CHNMC-07053
, 07053, CA180 121, NCT00788125
4.
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 74
Sponsor:
NCI
Protocol IDs:
080051
, 08-C-0051, NCT00923910
5.
Phase II Study of a Myeloablative Preparative Regimen Comprising Busulfan, Melphalan, and Thiotepa Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Hodgkin's or Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years and younger
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-04083-L
, OHSU-IRB-248, NCT00238433
6.
Phase II Study of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer or Other Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years old and under
Sponsor:
NCI
Protocol IDs:
CCCWFU-29506
, CCCWFU 29506, NCT00453206, CCCWFU-IRB00001366
7.
Phase II Study of Graft-Versus-Host Prophylaxis Comprising Sirolimus, Tacrolimus, and Anti-Thymocyte Globulin in Patients Undergoing Unrelated-Donor Hematopoietic Cell Transplantation For Hematological Malignancy
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
2 and over
Sponsor:
NCI
Protocol IDs:
CHNMC-06141
, 06141, NCT00589563
8.
Phase II Study of Unrelated Donor Umbilical Cord Blood Transplantation Using a Reduced-Intensity Preparative Regimen in Patients With Hematological Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2239.00
, 6722, FHCRC-IR-6722, NCT00723099
9.
Phase II Study of Early Administration of Low-Dose Anti-Thymocyte Globulin followed by Low-Dose Cyclophosphamide, Busulfan, and Fludarabine to Optimize Outcome of Reduced-Intensity Conditioning for Allogeneic Peripheral Blood Progenitor Cell Transplantation From a Matched Related Donor in Patients With Lymphomas, Hodgkins Disease, Leukemias, Myelodysplastic Syndrome or Renal Cell Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
BMTGG-NSH-807
, NSH 807, NCT00787761
10.
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0604)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
1 to 70
Sponsor:
NCI, NHLBI
Protocol IDs:
606
, U01 HL069294, NCT00864227
11.
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P2 L-D AB
, NCT00917826
12.
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
0 to 65
Sponsor:
Other
Protocol IDs:
2009-0266
, NCT01010217
13.
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
0 to 26
Sponsor:
Other
Protocol IDs:
CHNY 525
, AAAB2879, NCT01049854
14.
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
CHNY-02-516
, IRB# AAAB3095, NCT01050439
15.
Phase I Study of Bevacizumab and AZD2171 in Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
15 and over
Sponsor:
NCI
Protocol IDs:
MDA-MDACC-2005-0910
, MDACC 2005-0910, 7534, NCT00458731
16.
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
2 to 21
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0007
, 08-C-0007, NCI-P6068, 7458, NCT00556881
17.
Phase I Study of Autologous or Allogeneic LMP-Specific Cytotoxic T-Lymphocytes in Patients With Epstein-Barr Virus (EBV)-Positive Lymphoma, Lymphoepithelioma, or Severe Chronic Active EBV Infection Syndrome
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
BCM-H-9936-ALCI
, H 9936, NCT00671164
18.
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and under
Sponsor:
Other
Protocol IDs:
NKHEM
, NCT00697671
19.
Doxil, Bevacizumab and Temsirolimus Trial
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
12 and over
Sponsor:
Other
Protocol IDs:
2008-0384
, NCT00761644
20.
Study of Temsirolimus, Topotecan, and Bortezomib
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2008-0425
, NCT00770731
21.
Sirolimus and Cetuximab in Advanced Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2009-0226
, NCT00940381
22.
Infusion of Expanded Cord Blood T Cells
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
6 months to 55 years
Sponsor:
Other
Protocol IDs:
2006-0075
, NCT00972101
23.
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2009-0521
, NCT01015222
24.
Study of T-Regulatory Cell Kinetics in Patients With Leukemia, Advanced Hodgkin or Non-Hodgkin Lymphoma, or Myelodysplastic/Myeloproliferative Disease Receiving Alemtuzumab and Undergoing Stem Cell Transplantation From HLA Mismatched-Related Donors or HLA Matched-Unrelated Donors
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
BCM-H-21079
, H-21079, BCM-REGALE, NCT00647010
Select All on Page
Help with Results
